Frequently used therapeutic antimicrobials and their resistance patterns on Staphylococcus aureus and Escherichia coli in mastitis affected lactating cows

ABSTRACT

Mastitis is one of the most frequent and costly production diseases of dairy cattle. It is frequently treated with broad-spectrum antimicrobials. The objectives of this work were to investigate the prevalence of Staphylococcus aureus and Escherichia coli, find out the antimicrobials used in mastitis treatment, and explore the antimicrobial resistance profile including detection of resistance genes. Bacterial species and antimicrobial resistance genes were confirmed by the polymerase-chain reaction. A total of 450 cows were screened, where 23 (5.11%) and 173 (38.44%) were affected with clinical and sub-clinical mastitis, respectively. The prevalence of S. aureus was 39.13% (n = 9) and 47.97%(n = 83) while, E. coli was 30.43% (n = 7) and 15.60% (n = 27) in clinical and sub-clinical mastitis affected cows, respectively. The highest antimicrobials used for mastitis treatment were ciprofloxacin (83.34%), amoxycillin (80%) and ceftriaxone (76.67%). More than, 70% of S. aureus showed resistance against ampicillin, oxacillin, and tetracycline and more than 60% of E. coli exhibited resistance against oxacillin and sulfamethoxazole-trimethoprim. Selected antimicrobial resistance genes (mecA, tetK, tetL, tetM, tetA, tetB, tetC, sul1, sul2 and sul3) were identified from S. aureus and E. coli. Surprisingly, 7 (7.61%) S. aureus carried the mecA gene and were confirmed as methicillin-resistant S. aureus (MRSA). The most prevalent resistance genes were tetK 18 (19.57%) and tetL 13 (14.13%) for S. aureus, whereas sul1 16 (47.06%), tetA 12 (35.29%), sul2 11 (32.35%) and tetB 7 (20.59%) were the most common resistance genes in E. coli. Indiscriminate use of antimicrobials and the presence of multidrug-resistant bacteria suggest a potential threat to public health.

1. Introduction

Bovine mastitis remains a highly complex production disease. It poses a great economic challenge for the dairy industries throughout the globe. Diverse groups of pathogens such as bacteria, fungi and mycoplasma have been involved as its causal agents [1]. Around 137 different organisms have been identified as the causal agents of bovine mastitis all over the world [2]. Among them, bacteria are the most common and significant aetiological agent of bovine mastitis occurs in both clinical and sub-clinical forms. However, the most frequent causal agents associated with mastitis are Staphylococcus aureus and Escherichia coli [3]. Moreover, clinical mastitis is readily detectable based on clinical signs (e.g. pain and/or swelling in the mammary gland) and the presence of abnormal milk (e.g. clots, wateriness). Whereas, in sub-clinical mastitis, the clinical signs and abnormalities in milk are not detectable [4]. The economic losses associated with the clinical and sub-clinical forms of the disease arise from treatment costs, production loss in the form of reduced milk production, genetic potential loss, including culling and death of the affected cows [5].

Mastitis is one of the major reasons for the extensive use of antimicrobials in lactating cows [6–8]. Unfortunately, continuous selective antimicrobial pressure for the treatment and control of bovine mastitis may raise the likelihood of antimicrobial-resistant bacterial strains [7,9]. However, the emergence of these novel antimicrobial-resistant bacteria is one of the principal factors for the failure of recovery from mastitis [10]. So, antimicrobial resistance to mastitic pathogens is a well-documented major challenge for dairy cows’ treatment and management [11]. Furthermore, indiscriminate administration of antimicrobials without susceptibility testing as well as failure to maintain a standard therapeutic dose are considered other significant reasons for treatment failure in mastitis [12]. These misuses of broad-spectrum antimicrobials increase economic losses due to costly treatment processes and also encourage the acquisition of antimicrobial resistance genes from other bacteria in dairy farm environments [7]. Therefore, assessing antimicrobial resistance at the genetic level is of utmost importance to evaluate the determinants of antimicrobial resistance among bacterial pathogens. Moreover, the potential impact of antibiotic residues in milk and transmission of resistant bacteria to humans via the food chain has possible implications for human health.

Exploring the antibiotic resistance pattern of mastitic pathogens is an urgent prerequisite for the implementation of curable therapeutic guidelines and effective control of bovine mastitis. To date, bacteriological and antimicrobial resistance studies of bovine mastitis have not been fully performed in Bangladesh, in particular, the molecular detection of resistance genes is limited. Therefore, considering all the facts, the present study was undertaken to determine the prevalence of S. aureus and E. coli in clinical and sub-clinical mastitis affected lactating cows and, explore the different classes of antimicrobials administered in the treatment of bovine mastitis. We further aimed to evaluate the current antibiogram trend of S. aureus and E. coli and also detect the selected antimicrobial resistance genes of these pathogens.

2. Materials and methods

2.1. Statement of ethics and farm owner consent

The present study was performed according to the ethical guidelines of Chattogram Veterinary and Animal Sciences University (CVASU, Chattogram, Bangladesh). Verbal permission from the dairy farm owners has been taken and minimum discomforts of lactating cows were strictly ensured during screening of the animals and sample collection. All procedures were carried out under the approval of the Ethics Committee of CVASU [Approval no. CVASU/Dir (R&E) EC/2019/41 (2/8)].

2.2. Study area and duration

The present cross sectional study was conducted in Shikalbaha and Bandar thana of Chattogram District from November 2018 to June 2020. The area is popularly known as livestock production as well as milk pocket area of Chattogram district. Most of the farmers rear crossbred cows (Holstein-Friesian x Indigenous) are mostly in intensive system for milk production.

2.3. Study population and data collection

A total of 30 dairy farms (any farm comprised more than 10 lactating cows) were selected based on previous history of antimicrobials used, mastitis records and presences of clinical mastitis cases in the herd. All the farms were sampled in morning and not more than two farms were sampled in a single day. Pre-tested questionnaires were used for the collection of possible antimicrobials used in clinical and sub-clinical mastitis treatment purposes.

2.4. Diagnosis of clinical and sub-clinical mastitis

Clinical mastitis was confirmed based on clinical signs, including hard and inflamed udder, touch to pain, abnormal size and consistency of mammary gland, secretion of abnormal milk (presence of flack, clots, wateriness and pus) and blood-stained milk. At the same time, associated generalized clinical signs such as raises in body temperature, dullness and depression, loss of appetite, and sudden significant reduction of milk production are also considered.

California Mastitis Test was performed for the screening of sub-clinical mastitis in each individual cow. The test was performed according to the protocol described by Rana et al. [13]. Briefly, 2 mL of milk was taken from individual quarters of tested cows in each well of CMT paddles, and equal amounts of CMT reagents were added. The test sample was mixed in a gentle circular motion for 30 seconds. Sub-clinical mastitis was confirmed based on CMT results, the nature of the coagulation and the viscosity of the test mixture. Finally, the test results were interpreted as negative (0 or trace), weakly positive (+); distinctly positive (+ +) and strongly positive (++ +) according to the instructions described by Abebe et al. [14]. A cow was considered positive for sub-clinical mastitis when samples from at least one of the udder quarters tested positive for the California Mastitis Test (CMT) test.

2.5. Milk sampling

After the confirmation of clinical and sub-clinical mastitis, the teats of the cow were disinfected with 70% ethyl alcohol. Before sampling, the first squirt of milk was discarded and approximately 5 mL of milk was collected aseptically into a sterile test tube for microbiological analysis. All the samples were finally transferred to the laboratory by maintaining a proper cooling chain using an icebox. All milk samples were kept at room temperature before streaking into the agar plate.

2.6. Isolation, identification and PCR confirmation of S. aureus and E. coli from mastitic milk

Bacterial species were identified based on standard bacteriological procedures described by Ali et al. [15] and Gao et al. [16]. In brief, from respective samples, 20 µL of milk was streaked on a 5% bovine blood agar (Oxoid Ltd., Basingstoke, UK) plate and incubated for up to 48 hr at 37°C and the plate was examined every 24 hr interval for optimum growth of desired bacteria. The characteristic appearance of staphylococcus colony is smooth, yellow, pigmented, raised, and with complete or incomplete haemolysis. Suspected colonies were further sub-cultured on Mannitol Salt Agar or MSA (Oxoid Ltd., Basingstoke, UK) and incubated at 37°C for 48 hr. Finally, the Gram’s staining, catalase, and tube coagulase tests were performed on bacterial colonies that fermented MSA. Similarly, suspected E. coli colonies (round, thick, moist, smooth, greyish white) were further sub-cultured on MacConkey agar (Oxoid Ltd., Basingstoke, UK) and Eosin methylene blue (EMB) agar and incubated at 37°C for 24 hr. Then, the Gram’s staining, Triple Sugar Iron (TSI) test, Indole, Methyl red, Voges-Proskauer and Citrate utilization (IMViC) tests were performed for biochemical confirmation of E. coli.

All primarily isolated S. aureus were further confirmed by PCR targeting the 23S rRNA gene described previously by Shome et al. [17] (Table 1) While, E. coli species were confirmed by targeting the housekeeping gene (adenylate kinase, adk) described by Das et al. [18] (Table 1). All isolates were stored at −80°C using 50% glycerol until further examination [19].

Table 1.

Primers used for the amplification of S. aureus and E. coli species and antimicrobial resistance genes

Target genes	Oligonucleotide primer sequences (5̍-3̍)	Reference
23S rRNA	AGCGAGTCTGAATAGGGCGTTT CCCATCACAGCTCAGCCTTAAC	Shome et al. [17]
adk	ATTCTGCTTGGCGCTCCGGG CCGTCAACTTTCGCGTATTT	Das et al. [18]
mecA	TCCAGATTACAACTTCACCAGG CCACTTCATATCTTGTAACG	Larsen et al. [22]
tetK	GTAGCGACAATAGGTAATAGT GTAGTGACAATAAACCTCCTA	Haubert et al. [23]
tetL	TCG TTA GCG TGC TGT CAT TC GTA TCC CAC CAA TGT AGC CG
tetM	GTG GAC AAA GGT ACA ACG AG CGG TAA AGT TCG TCA CAC AC
tetA	GGCGGTCTTCTTCATCATGC CGGCAGGCAGAGCAAGTAGA	Boerlin et al. [24]
tetB	CATTAATAGGCGCATCGCTG TGAAGGTCATCGATAGCAGG
tetC	GCTGTAGGCATAGGCTTGGT GCCGGAAGCGAGAAGAATCA
sul1	GTGACGGTGTTCGGCATTCT TCCGAGAAGGTGATTGCGCT
sul2	CGGCATCGTCAACATAACCT TGTGCGGATGAAGTCAGCTC
sul3	GAGCAAGATTTTTGGAATCG CATCTGCAGCTAACCTAGGGCTTTGGA

2.7. Antimicrobial susceptibility testing

All S. aureus (92) and E. coli (34) bacterial isolates were screened for susceptibility testing using the standard disk diffusion method against 13 different antimicrobial compounds comprising 7 different classes. The antimicrobial panels (Oxoid, Basingstoke, UK) were used, namely: penicillin (10 IU), ampicillin (10 μg), amoxycillin-clavulanic acid (10 μg), cefoxitin (10 μg), ceftriaxone (10 μg), cefaclor (30 μg), ciprofloxacin (10 μg), gentamicin (30 μg), tetracycline (30 μg), erythromycin (15 μg), oxacillin (5 μg), sulfamethoxazole-trimethoprim (1.25 + 23.75 μg), and streptomycin (100 μg). For each isolate, the zone of inhibition around each disk was measured and interpreted as susceptible (S), intermediate (I) and resistant (R) according to the Clinical and Laboratory Standards Institute (CLSI) guidelines [20]. S. aureus and E. coli isolates that exhibit resistance against ≥3 antimicrobial classes were considered multidrug-resistant (MDR) [21].

2.8. Detection of resistance genes

The resistant S. aureus isolates (25) to cefoxitin were further screened for the detection of the mecA gene by PCR described earlier by Larsen et al. [22] (Table 1) and tetracycline-resistant isolates were confirmed by the presence of the tetK, tetL and tetM genes described by Haubert et al. [23] (Table 1). Also, E. coli isolates which showed phenotypic resistance to tetracycline and sulphonamides, were subsequently confirmed by targeting major resistant genes. The tetA, tetB, tetC genes were detected for tetracycline while, sul1, sul2, sul3 genes were detected for sulphonamides by using specific primer sequences previously reported by Boerlin et al. [24] (Table 1). Previously confirmed MRSA strains encoded the mecA gene [25], and E. coli harboured the tetracycline and sulphonamides resistant genes [18] were used as positive controls, while nuclease-free water was used as negative controls for every PCR reaction.

2.9. Statistical analysis

Data obtained from the laboratory and field questionnaires were entered into the Microsoft Excel 2010. The descriptive statistics (percent’s) and the 95% confidence interval of the prevalence values were calculated by the modified Wald method using the Graph Pad Quick Calcs online tool (www.graphpad.com/quickcalcs/). The prevalence of clinical and sub-clinical mastitis was calculated by dividing the number of clinical or sub-clinical mastitis affected cows by the total number of cows tested as the denominator. In addition, the prevalence of S. aureus and E. coli were enumerated by the number of positive isolates by the total number of mastitis-positive cows sampled as the denominator. Finally, the percentages of resistance genes were determined by the total number of S. aureus and E. coli positive isolates as the denominator. Furthermore, the heat map and bar diagram were created using Graphpad Prism (version 7).

3. Results

3.1. Samples

In total, 30 dairy farms were screened for clinical and sub-clinical mastitis. Of them, 14 [46.67%, 95% Confidence Interval (CI): 30.23–63.86] farms were positive for clinical mastitis while, all of the farms (100%, 95% CI: 86.53–100) were positive for sub-clinical mastitis (Figure 1). Furthermore, a total of 450 lactating cows (1800 quarters) were randomly screened for identification of sub-clinical mastitis on 30 dairy farms (Table 2). Of them, 173 (38.44%, CI: 34.06 to 43.02) cows were found positive for the CMT test and identified as having sub-clinical mastitis (Table 2). In addition, 23 out of 450 cows (5.11%, 95% CI: 3.27 to 7.57) were found affected with clinical mastitis showing clinical signs and symptoms during the farm visits (Table 2).

Figure 1.

Heat map showing the distribution of types of mastitis circulating in different dairy farms and, various combined antimicrobials used for the treatment of clinical and sub-clinical mastitis, as well as the presence of diverse antimicrobial resistance genes in S. aureus and E. coli isolates. Each row represents an individual dairy farm. Where, AMX-CLOXA = Amoxycillin- Cloxacillin, AMX-CRO = Amoxycillin- Ceftriaxone, AMX-GEN = Amoxycillin- Gentamicin, PEN-STR = Penicillin- Streptomycin, N-KAN = Neomycin- Kanamycin, SXT = Sulfamethoxazole-Trimethoprim, TET-GEN = Tetracycline- Gentamicin, SXT-N-KAN = Sulfamethoxazole-Trimethoprim- Neomycin- Kanamycin.

Table 2.

Prevalence of S. aureus and E. coli in clinical and sub-clinical mastitis affected cows

Total number of dairy farms	Total number of cows screened	Mastitis affected cows (%)	PCR confirmed S. aureus (%)	PCR confirmed E. coli (%)
30	450 (1800 quarters)	Clinical 23 (5.11%)	9 (39.13)	7 (30.43)
		Sub-clinical 173 (38.44%)	83 (47.97)	27 (15.60)

3.2. Grading of bovine clinical and sub-clinical mastitis based of CMT

Among 450 lactating cows, 254 (56.45%, 95% CI: 51.83 to 60.95) animals were found CMT negative, 43 (9.56%, 95% CI: 7.15 to 12.65) were identified as weakly positive (+) and 68 (15.11%, 95% CI: 12.09 to 18.73) were distinctly positive (++) and 62 (13.78%, 95% CI: 10.88 to 17.28) were diagnosed as strongly positive (+++) for sub-clinical mastitis. However, all of the 23 (5.11%, 95% CI: 3.40 to 7.59) clinical mastitis cases were found to be strongly positive (+++) for the CMT.

3.3. Prevalence of S. aureus and E. coli in clinical and sub-clinical mastitis affected cows

In total, 196 clinical and sub-clinical mastitic samples were cultured with S. aureus being the most prevalent pathogen in both cases, which were 9/23 (39.13%, 95% CI: 22.10 to 59.27) and 83/173 (47.98%, 95% CI: 40.66 to 55.38), respectively (Table 2). Interestingly, all dairy farms were positive for S. aureus and associated with bovine mastitis. Among the 92S. aureus isolates, 34 (36.96%, 95% CI: 27.79 to 47.17) were found to be positive for coagulase test and the remaining 58 (63.04%, 95% CI: 52.83 to 72.21) were identified as coagulase test negative. The prevalence of E. coli was found to be 7/23 (30.43%, 95% CI: 15.41 to 51.06) and 27/173 (15.61%, 95% CI: 10.90 to 21.81) in clinical and sub-clinical mastitis affected cows, respectively (Table 2).

3.4. Frequency of antimicrobial used in dairy farm

We found that 12 different kinds of antimicrobials were used in 30 different dairy farms. Among them, the highest antimicrobials used for mastitis treatment were ciprofloxacin in 25 (83.33%) farms; amoxycillin in 24 (80%) farms; ceftriaxone in 23 (76.67%) farms, and gentamicin in 22 (73.33%) farms (Figure 2). Besides, penicillin and streptomycin were used in 19 (63.33%) farms, tetracycline in 17 (56.67%) farms, cloxacillin in 16 (53.33%) and sulfamethoxazole-trimethoprim in 13 (43.33%) farms at the second highest level. The frequency of neomycin 7 (23.33%), and kanamycin 7 (23.33%) usage in the dairy farms were minimal (Figure 2).

Figure 2.

Diverse group of antimicrobials used in dairy farms for the treatment of clinical and sub-clinical mastitis. Where, AMX = Amoxycillin, AMP = Ampicillin, CRO = Ceftriaxone, CLOXA = Cloxacillin. CIP = Ciprofloxacin, GEN = Gentamicin, KAN = Kanamycin, N = Neomycin, PEN = Penicillin, STR = Streptomycin, SXT = Sulfamethoxazole-trimethoprim, TET = Tetracycline.

3.5. Combination of antimicrobial used for mastitis treatment

Interestingly, all of the dairy farms (n = 30) used more than 3 antimicrobial classes for mastitis treatment, while 23 (76.67%) farms administered different combined antimicrobials in different combinations (Figure 1). Among them, a maximum of 19 (63.33%) farms used amoxycillin-cloxacillin and 17 (56.67%) farms used amoxycillin-gentamicin combined antimicrobials for mastitis treatment. There were 7 (23.33%) farms used single antimicrobials for therapeutic purposes (Figure 1).

3.6. Antimicrobial susceptibility profiles

All the S. aureus and E. coli isolates were found to be multi-drug resistant (MDR) (i.e. resistant to ≥ 3 antimicrobial classes). Among the S. aureus isolates, the highest resistance was observed for tetracycline (76.09%), oxacillin, and ampicillin (70.65%) (Table 3). More than 58% of the isolates exhibited resistance against erythromycin, amoxycillin-clavulanic acid and streptomycin. In the case of E. coli, this exhibits the highest resistance against oxacillin (64.71%) and ampicillin (58.82%) antibiotics. More than 70% of E. coli isolates were sensitive to ceftriaxone, ciprofloxacin and cefaclor (Table 3).

Table 3.

Antimicrobial sensitivity profile of S. aureus and E. coli in clinical and sub-clinical mastitis affected cows

Organism	Antimicrobial susceptibility	AUG	AMP	CRO	CEC	FOX	CIP	ERY	GEN	OXA	PEN	STR	SXT	TET
S. aureus (92)	Sensitive (%)	38 (41.30)	27 (29.35)	65 (70.65)	48 (52.17)	67 (72.83)	60 (65.22)	38 (41.30)	33 (35.87)	27 (29.35)	44 (47.83)	38 (41.30)	48 (52.17)	22 (23.91)
	*Resistant (%)	54 (58.70)	65 (70.65)	27 (29.35)	44 (47.83)	25 (27.17)	32 (34.78)	54 (58.70)	59 (64.13)	65 (70.65)	48 (52.17)	54 (58.70)	44 (47.83)	70 (76.09)
E. coli (34)	Sensitive (%)	18 (52.94)	14 (41.18)	25 (73.53)	24 (70.59)	23 (67.65)	25 (73.53)	26 (76.47)	23 (67.65)	12 (35.29)	19 (55.88)	23 (67.65)	13 (38.24)	19 (55.88)
	*Resistant (%)	16 (47.06)	20 (58.82)	9 (26.47)	10 (29.41)	11 (32.35)	9 (26.47)	8 (23.53)	11 (32.35)	22 (64.71)	15 (44.12)	11 (32.35)	21 (61.76)	15 (44.12)

*All intermediately resistant isolates are considered as susceptible. Where, AUG = Amoxycillin-Clavulanic acid, AMP = Ampicillin, CRO = Ceftriaxone, CEC = Cefaclor, FOX = Cefoxitin, CIP = Ciprofloxacin, ERY = Erythromycin, GEN = Gentamicin, OXA = Oxacillin, PEN = Penicillin, STR = Streptomycin, SXT = Sulfamethoxazole-Trimethoprim, TET = Tetracycline.

3.7. Antimicrobial resistance genes profile of S. aureus and E. coli

A total of 10 resistance genes including mecA, tetK, tetL, and tetM, were evaluated for S. aureus. The tetA, tetB, tetC, sul1, sul2, and sul3, were screened for E. coli isolates. Among the S. aureus isolates, 7/92 (7.61%) encoded the mecA gene, which is classified as methicillin-resistant S. aureus (MRSA) and 19.57% (18/92) tested isolates carried tetK gene (Figure 1) (Table 4). In the case of E. coli isolates, the most prevalent antimicrobial resistance genes were tetA 12/34 (35.29%) and tetB 7/34 (20.59%) encoding resistant to tetracycline followed by sul1 16/34 (47.06%) and sul2 11/34 (32.35%), encoding resistant to sulphonamides (Figure 1) (Table 4).

Table 4.

Prevalence of different antimicrobial resistance genes encoded by S. aureus and E. coli.

Organism	Resistance genes	Prevalence
S. aureus (92)	mecA	7 (7.61%)
	tetK	18 (19.57%)
	tetL	13 (14.13%)
	tetM	6 (6.52%)
E. coli (34)	tetA	12 (35.29%)
	tetB	7 (20.59%)
	tetC	2(5.88%)
	sul1	16 (47.06%)
	sul2	11(32.35%)
	sul3	4(11.76%)

4. Discussion

In the present study, the overall prevalence of sub-clinical mastitis at cow level was 38.44% and the smallest proportion (5.11%) was suffered from clinical mastitis. This finding was consistent with the previous reports of Ramírez et al. [11,26]. The prevalence of clinical and sub-clinical mastitis was slightly higher in Eastern Ethiopia, which was 12.5% and 51.8%, respectively [27]. The occurrence of mastitis in lactating cows varies due to the geographical location, breed, age, stages of lactation, status of the udder, number of parity, immunity, management, hygiene, and milking practices in dairy farms [26,28]. However, the predominant sub-clinical mastitis in the current study area is an alarming problem that not only causes economic losses through reducing milk production but also adversely affects the human food chain.

Both S. aureus and E. coli are the predominant causal agents of bovine clinical and sub-clinical mastitis all over the world [23] including Bangladesh. However, in both clinical and sub-clinical cases, the most frequently isolated organism was S. aureus, which represented 39.13% and 47.98%, respectively. The isolation rate was closely similar to the studies conducted in Italy (41%) [29] and slightly higher in Brazil (56%) [30]. Among S. aureus, 36.96% was found to be coagulase positive, which was closely similar to the previous findings [31]. These coagulase positive S. aureus strains are most frequently associated with contagious mastitis of bovine, caprine and ovine species due to the harbouring of multiple virulence factors such as Staphylococcal Protein-A, the coagulase enzyme, clumping factors, haemolysins, proteases and gelatinases [13,23,32].

Moreover, E. coli also causes environmental fatal mastitis and their frequency varies according to farm management, hygienic practices, and the presence of virulence factors. Surprisingly, any type of mastitis in the mammary gland always first attempts to be treated with antimicrobials to reduce the fatal consequence, especially to control the contagious infections [6]. In the present study, we found that all of the dairy farms administered different categories of antimicrobials (penicillin, β-lactams, fluoroquinolones, tetracyclines, aminoglycoside and sulphonamide) ranging from narrow to broad-spectrum to treat the clinical and sub-clinical mastitis. Another significant concern was the high number of dairy owners who used combined antimicrobials in a combination of different classes for the treatment of clinical and sub-clinical mastitis. Unfortunately, the widespread and indiscriminate administration of antimicrobials induces the development of resistance among mastitis bacteria [33]. The repetitive exposure of a similar or wide range of antimicrobials for the treatment of chronic/sub-clinical mastitis play a key trigger for antimicrobial resistance and contribute to acquire resistant genes. Our results demonstrated that all isolates were multidrug-resistant and showed resistance to three or more classes of antimicrobials [21]. This finding indicates the emergence of antimicrobial resistance in S. aureus and E. coli from masitic milk samples in Bangladesh. Moreover, the number of resistant bacteria evolved in increasing trend from bovine mastitis cases that have potential chance to spread in the human food chain and poses a zoonotic burden in environment.

Since the screening of antimicrobial resistance genes, both S. aureus and E. coli isolates harboured multiple types of resistance genes. According to different mastitis research, it is focused that β-lactams antimicrobials are most frequently used in both parental and intramammary routes in lactating cows for treatment of mastitis infection [34,35]. In the present study, high antimicrobial resistance frequency to the β-lactams penicillin (52.17%), amoxycillin-clavulanic acid (58.70%), ampicillin (70.65%), oxacillin (70.65%) was observed, which is closely supported by previous findings of Priyantha et al. [34]; Haubert et al. [23]. According to previous findings, S. aureus and E. coli resistance to penicillin, ampicillin, amoxycillin, and oxacillin is the most common type of antimicrobial resistance among mastitis-causing bacteria [9,11,13,34]. The high resistance frequency of E. coli against sulfamethoxazole-trimethoprim (61.76%) was reported in several previous studies [9,34]. We noted that S. aureus and E. coli displayed a high proportion of susceptibility to ceftriaxone (70.65% and 73.53%) and ciprofloxacin (65.22% and 73.53%) which was consistent with the findings of previously published reports [9,13,15]. The high rate of susceptibility to ceftriaxone and ciprofloxacin might be due to less exposure in dairy farm environments as well as the broad-spectrum nature of these antimicrobials.

Interestingly, in the present study 7 (7.61%) S. aureus isolates carried the mecA gene and all MRSA isolates exhibit resistance to cefoxitin, oxacillin and penicillin, and these findings were almost similar to the previous studies by Rana et al. [13]; Chajecka-Wierzchowska et al. [36]. The mecA gene is extensively found in staphylococci isolates which confer the resistance to β-lactams antimicrobials and this resistant gene arises from a chromosomally integrated mobile genetic element namely staphylococcal cassette chromosome mec (SCCmec) [37]; which encodes modified penicillin-binding protein (PBP). Although few studies have reported the presence of the mecA gene in S. aureus at low levels in bovine and caprine mastitis [13,38,39], but the widespread presence of it creates a potential challenge for clinical management of mastitis. Moreover, these resistant isolates are readily transferable from livestock to humans that make a potential zoonotic burden. The MSRA isolates constantly display resistance against a wide range of broad spectrum antimicrobial agents, including all β-lactams antimicrobials (penicillin, methicillin, oxacillin, cefoxitin, amoxycillin-clavulanic acid, amoxycillin-sulbactam), quinolones, tetracycline, macrolides and chloramphenicol [22,32,40].

Fluoroquinolones, tetracyclines and sulphonamides are broad-spectrum antimicrobial agents administered in mastitis cows for clinical recovery of infection [36]. We noted that both S. aureus and E. coli showed 76.09% and 44.12% resistance against tetracycline, respectively. Moreover, the presence of tetA, tetB, tetC, tetK, tetL and tetM genes conferred the efflux proteins or ribosomal protection proteins that trigger the high resistance against tetracycline antibiotics. The presence of a tetracycline resistance gene among S. aureus and E.coli from clinical and sub-clinical mastitis affected cows has been reported in several previous studies [23,28,34]. In the present study, S. aureus and E. coli harboured tetK and tetA genes at the highest frequencies, which were 19.57% and 35.29%, respectively. However, the presence of other tetracycline resistance genes is found at a lower rate in bovine mastitis cases and these findings was in agreement with previous studies of Ashraf et al. [28]; Haubert et al. [23]. Furthermore, several studies discloses that the widespread distribution of tetracycline resistance determinants among different organisms is largely due to the acquisition or encoding of mobile genetic elements like readily transferable conjugative plasmids or transposons [41].

In the current study, the sulphonamide resistance genes that inhibit the folate pathways like sul1 (47.06%), sul2 (32.35%), and sul3 (11.76%) were detected in E. coli isolates. The frequencies of résistance genes are significantly higher than previous studies by Frey et al. [42] who described only 5% isolates carrying sulphonamide resistance genes in bovine mastitis cases. However, the presence of sulphonamide resistance genes in E. coli at higher rates in raw milk and milk products, which may originate from clinical or sub-clinical mastitis, affected lactating cows in the dairy farm [30].

Due to resource limitations, sulphonamide resistance genes for S. aureus, was not detected in the present study. The emergence of multidrug-resistant (MDR) organisms in dairy herds is a serious threat that is resulting in significant increases in veterinary as well as medication costs for treatment and management of bovine mastitis. Generally, the MDR phenomenon is significantly triggered by the spontaneous and irrational use of widespread antimicrobials and acquiring of multiple antimicrobial resistance genes through cross-transmission, mutation or from environments [21,32,41]. Therefore, it is an urgent need to monitor and control the irrational use of antimicrobial agents and the exemplary mastitis treatment guidelines should be based on the laboratory reports of the antimicrobials sensitivity test.

5. Conclusion

This study demonstrated that sub-clinical type mastitis is highly prevalent in dairy farms and S. aureus is confirmed as the most prevalent pathogen associated with both clinical and sub-clinical bovine mastitis. Alarmingly, all dairy farms used broad-spectrum antimicrobials, especially ciprofloxacin, amoxycillin, and ceftriaxone for the treatment of bovine mastitis. Moreover, the presence of MRSA strains and the encoding of different resistance genes on S. aureus and E.coli isolates in mastitic cows is an alarming report and might pose a serious challenge to the clinical management of bovine mastitis. Therefore, it is of utmost importance to conduct routine surveillance programs to regulate the use of antimicrobial agents and detect the potential transfer of antimicrobial resistance genes on dairy farms.

Funding Statement

This research was financially supported by the Ministry of Science and Technology [Grant no. 5229], The People’s Republic of Bangladesh.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Author’s contribution

Eaftekhar Ahmed Rana: Conceptualization, Funding acquisition, Data curation, Investigation, Methodology, Project administration, Resources, Validation, Formal analysis, Visualization, Writing original draft, Writing- review and editing. Md Abul Fazal: Formal analysis, Investigation and Methodology. Mohammad Abdul Alim: Supervision; Visualization, Validation, Writing- review and editing.

Compliance with ethical standards

During conducting the study, source of funding, animal welfare ethics, and entire laboratory protocols were strictly followed by all authors.

Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article.

Ethical approval statement

Ethical approval was received from the institutional ethical approval committee of Chattogram Veterinary and Animal Sciences University (Approval no. CVASU/Dir (R&E) EC/2019/41 (2/8)).